Updated:
IO Biotech, Inc.
IO Biotech is a clinical-stage biotechnology firm developing immune-modulating cancer vaccines, led by CEO Mai-Britt Zocca and publicly traded on Nasdaq.
IO Biotech, Inc.
IO Biotech was founded in 2014 by a Danish scientific team, with CEO Mai-Britt Zocca leading the company. The firm's wealth origin is tied to venture capital and public equity financing, having gone public on the Nasdaq in 2021 via an IPO that raised approximately $148.8 million (per SEC filings). The company is headquartered in Copenhagen, Denmark. The firm's strategy centers on immune-modulating cancer vaccines that combine checkpoint inhibitors with T-cell stimulation. Its lead candidate, IO102-IO103, is being tested in combination with pembrolizumab (Keytruda) for first-line advanced melanoma in a Phase 3 trial as of mid-2023. Pipeline assets also target non-small cell lung cancer and other solid tumors, with the firm employing a platform technology that can be adapted across cancer types. The geographic focus remains global through clinical trial sites. As a public company, IO Biotech reported approximately $42.9 million in cash and equivalents as of December 31, 2023 (per the firm's 2023 annual report). The firm employs roughly 30-40 professionals based on public disclosures, with operations primarily in Denmark and the United States. In June 2023, the firm announced results from the Phase 2 trial of IO102-IO103 in combination with pembrolizumab in advanced melanoma, showing a 79% overall response rate (per the firm's press release). The structural differentiator lies in IO Biotech's dual-targeting vaccine platform, which simultaneously targets PD-L1 and IDO immune checkpoints expressed in the tumor microenvironment. This distinguishes it from single-antigen cancer vaccines and allows for a multimodal immune response without systemic autoimmune activation.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at IO Biotech?
Investment decisions at IO Biotech are made by the company's board of directors and executive leadership, with CEO Mai-Britt Zocca and Chief Financial Officer Stacy J. Smith overseeing capital allocation. The firm's clinical development strategy is guided by Chief Medical Officer Dr. Adam Dubin. As a public company, strategic financial decisions are subject to board approval and shareholder oversight (per the firm's SEC filings).
What is the scientific approach behind IO Biotech's vaccines?
IO Biotech's vaccines are designed to target the tumor microenvironment by activating T-cells against two immune checkpoints: PD-L1 and IDO. The firm's lead candidate, IO102-IO103, aims to kill both the tumor cells and the immunosuppressive cells in the surrounding environment. This dual-targeting strategy distinguishes it from traditional cancer vaccines and aims to generate a more durable immune response (per public scientific publications).
Is IO Biotech structured as a single family office or a biotech firm?
IO Biotech is a publicly traded clinical-stage biotechnology company, not a family office. The firm is listed on the Nasdaq under ticker IOBI. While it may attract family office investment through public markets or private placements, its structure is that of a life sciences corporation focused on drug development and commercialization (per the firm's corporate filings).
Does IO Biotech participate in venture investments or only internal R&D?
IO Biotech focuses exclusively on internal R&D and clinical development of its proprietary vaccine platform. The firm does not operate as an investment vehicle or deploy capital in external ventures. Its partnerships, such as with Merck for pembrolizumab combination trials, are collaborations rather than financial investments (per the firm's public statements).
What investment stages does IO Biotech typically target?
As a drug developer, IO Biotech targets early to mid-stage clinical milestones, having advanced through Phase 1 and 2 trials and currently operating Phase 3 studies for its lead candidate. The firm's financing stages include venture rounds pre-IPO and public equity thereafter, but it does not invest in other companies at any stage (per public records).
Which sectors does IO Biotech explicitly avoid?
IO Biotech does not disclose explicit sector exclusions, but its operations are entirely within therapeutic oncology. The firm has no disclosed activities in diagnostics, medical devices, or non-cancer therapeutics (per the firm's pipeline disclosures).
How is IO Biotech related to its Danish origins?
IO Biotech was founded in Denmark and maintains its headquarters in Copenhagen. The company went public on the Nasdaq in 2021, moving to a US corporate structure for listing purposes. Its scientific roots remain Danish, with key R&D operations still conducted in Copenhagen alongside US-based clinical operations (per the firm's SEC filings).
Where does the underlying wealth come from?
IO Biotech's capital comes from institutional and retail public investors following its IPO in November 2021, which raised $148.8 million. Prior to that, the firm raised venture capital from Danish and international investors (per SEC filings). As a clinical-stage company, it does not generate revenue from product sales, so its wealth is entirely from equity financing.
Does IO Biotech maintain philanthropic structures?
IO Biotech does not maintain separate philanthropic structures. The firm's public filings and communications do not reference a foundation or charitable arm. Any philanthropic activities would be conducted by its executives or board members personally, not institutionally (per public records).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: